Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Global guidelines for the management of locally advanced or metastatic hormone receptor–positive (HR-positive), human epidermal growth factor 2–negative (HER2-negative) breast cancer recommend endocrine therapy as first-line treatment for all patients, regardless of age or postmenopausal status. How...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697769/ |